Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.

You may also be interested in...



Despite FDA Approval, Near Term U.S. Mircera Launch Appears Doubtful

Amgen has legal hold on the commercialization of Roche’s long-acting erythropoiesis stimulating agent for now.

Despite FDA Approval, Near Term U.S. Mircera Launch Appears Doubtful

Amgen has legal hold on the commercialization of Roche’s long-acting erythropoiesis stimulating agent for now.

Amgen EPO Patent Win Over Roche Could Derail Mircera Launch

Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel